411pain

Introduction

411pain is a commercial entity that operates within the health‑care sector, primarily focusing on the development, distribution, and support of pain management solutions. The company positions itself as a provider of integrated services that combine medical expertise, consumer education, and innovative technology to address the needs of individuals experiencing acute or chronic pain. As a publicly traded corporation listed on the NASDAQ under the ticker symbol PNDM, 411pain has established a presence in both domestic and international markets, offering a portfolio that includes prescription medication, over‑the‑counter products, and digital health platforms.

History and Founding

Early Years

The origins of 411pain trace back to 2011 when Dr. Angela Ruiz, a board‑certified pain specialist, identified a gap in the market for accessible, evidence‑based pain management resources. After establishing a small outpatient clinic in Palo Alto, California, Ruiz partnered with software developer Michael Thompson to create an informational website that provided self‑assessment tools and patient education. The website, initially titled “411 Pain Resources,” garnered rapid attention from both patients and clinicians.

Corporate Formation

In 2012, the company incorporated as 411 Pain Solutions, Inc., with a mission to democratize pain care through digital platforms and a network of clinical affiliates. The name “411” was chosen to evoke the familiar telephone directory assistance service, symbolizing the company’s intent to offer readily available guidance. Early funding was secured through a combination of angel investment and a seed round from venture capital firm HealthTech Ventures.

Expansion and Product Development

Between 2013 and 2015, 411pain launched its first suite of over‑the‑counter products, including topical analgesic creams and transcutaneous electrical nerve stimulation (TENS) devices. These products were marketed under the brand name “PainEase” and were distributed through major retail chains such as Walgreens and CVS. The company also introduced a subscription‑based telehealth platform in 2014, allowing patients to consult with pain specialists via video conferencing.

Public Offering

411pain went public on the NASDAQ in 2018, raising $120 million in its initial public offering. The IPO was led by investment bank Goldman Sachs, and the company used proceeds to expand its digital infrastructure, acquire complementary start‑ups, and scale its retail distribution network.

Corporate Structure

Organizational Hierarchy

The corporate governance structure of 411pain comprises a board of directors, an executive leadership team, and various functional departments. The board, chaired by former executive director of the American Academy of Pain Medicine, oversees strategic decisions, financial reporting, and regulatory compliance. The executive team includes a Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, Chief Technology Officer, and Vice Presidents for Marketing, Operations, and Regulatory Affairs.

Subsidiaries and Affiliates

411pain operates through several subsidiaries that focus on distinct aspects of the pain management ecosystem:

411Pain Digital Solutions LLC – responsible for the company’s telehealth services and mobile applications.
PainEase Pharmaceuticals – oversees the development and manufacturing of over‑the‑counter pain relief products.
411Pain Clinical Network – manages a network of outpatient clinics and specialist partnerships.
411Pain Analytics – provides data analytics services to healthcare providers and insurers.

Products and Services

Prescription Medications

411pain partners with several pharmaceutical manufacturers to provide prescription opioids and non‑opioid analgesics under a managed care program. The company’s formulary includes medications such as oxycodone, tramadol, and lidocaine patches, all of which are dispensed through a proprietary e‑prescription system integrated with national pharmacy networks.

Over‑the‑Counter (OTC) Products

Under the PainEase brand, 411pain offers a range of topical creams, gels, and patches that contain active ingredients such as menthol, capsaicin, and lidocaine. These products are sold through retail partners and direct‑to‑consumer channels. The company maintains a rigorous quality‑control protocol that meets FDA standards for OTC products.

Telehealth Platform

The 411pain telehealth platform provides virtual consultations, prescription management, and post‑treatment follow‑up. Patients register for the platform via a web portal or mobile application, completing a medical history questionnaire that feeds into the electronic health record system. The platform supports secure video calls, real‑time prescription uploads, and integration with wearable devices for activity monitoring.

Digital Health Tools

In addition to the telehealth service, 411pain offers several digital tools designed to assist patients in managing pain:

PainTracker App – a mobile application that logs pain intensity, medication usage, and activity levels.
Self‑Assessment Tool – an online questionnaire that helps patients determine the likely etiology of their pain and recommends appropriate resources.
Educational Resource Hub – a library of articles, videos, and webinars covering topics such as neuropathic pain, chronic back pain, and opioid stewardship.

Technology and Innovation

Artificial Intelligence for Pain Assessment

411pain has invested in machine‑learning algorithms that analyze patient‑reported outcomes and physiological data to predict pain flare‑ups. The AI models use natural language processing to interpret narrative entries in the PainTracker App and correlate them with external data sources such as sleep patterns and weather changes.

Electronic Health Record Integration

Integration with the national health information exchange network allows 411pain to exchange de‑identified patient data with hospitals, insurers, and other healthcare providers. This facilitates continuity of care and supports research into pain management outcomes.

Wearable Device Compatibility

The company has developed a standardized API that enables its telehealth platform to receive data from popular wearable devices. Features such as heart rate variability, movement metrics, and sleep quality are incorporated into clinical decision support tools that guide medication titration.

Market Presence

Domestic Reach

411pain’s retail footprint spans over 2,000 locations across the United States, including pharmacies, big‑box retailers, and specialty health stores. The company’s telehealth service has over 500,000 active users nationwide, with a patient satisfaction rate exceeding 90 percent according to internal surveys.

International Expansion

In 2020, 411pain entered the Canadian market through a joint venture with MediHealth Canada. The partnership allowed the company to introduce its PainEase products and digital services under the brand “PainEase Canada.” As of 2024, 411pain operates in Canada, the United Kingdom, and Australia, with plans to expand into the European Union.

Revenue Segmentation

Revenue is segmented across three primary categories: OTC sales (45 percent), prescription medication sales (30 percent), and telehealth services (25 percent). The company has experienced compound annual growth of 12 percent across all segments over the past five fiscal years.

Legal and Regulatory Issues

FDA Compliance

411pain’s OTC product line is subject to Federal Drug Administration regulations. The company conducts annual audits to ensure compliance with manufacturing, labeling, and safety requirements. In 2021, a temporary FDA hold was placed on a capsaicin patch due to a packaging defect; the issue was resolved within 90 days.

State Prescription Drug Monitoring Programs (PDMPs)

As part of its prescription management program, 411pain integrates with state PDMPs to track opioid prescriptions. The integration facilitates real‑time alerts for potential misuse and supports the company’s opioid stewardship initiatives.

Privacy and Data Protection

411pain adheres to the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR) for operations in the European Union. The company implements encryption, access controls, and breach‑notification protocols to safeguard patient data.

Public Perception and Criticisms

Opioid Stewardship Initiatives

411pain has been both praised and scrutinized for its approach to opioid prescribing. In 2019, the company released a set of guidelines that prioritize non‑opioid therapies for mild to moderate pain. Critics argue that the guidelines still rely heavily on opioid prescriptions for certain conditions.

Product Safety Concerns

In 2022, a class‑action lawsuit was filed alleging that a topical lidocaine patch caused skin irritation in a significant portion of users. The lawsuit was settled for $15 million, and the company has since updated its product labeling to include warnings about potential skin reactions.

Advertising Practices

Some patient advocacy groups have criticized 411pain’s advertising campaigns for oversimplifying pain conditions. In response, the company adopted a new communication strategy in 2023 that emphasizes evidence‑based information and patient stories.

Notable Partnerships and Collaborations

Academic Research Collaborations

411pain partners with the University of California, San Diego to conduct clinical trials on novel analgesic compounds. The partnership includes joint grant applications to the National Institutes of Health and shared data analytics resources.

Insurance Partnerships

411pain has secured agreements with several major insurers, including UnitedHealth Group and Aetna, to include its telehealth services in employer wellness programs. These collaborations provide coverage for virtual pain consultations and prescription management.

Technology Partnerships

In 2021, 411pain entered a strategic alliance with HealthData Inc. to develop a predictive analytics platform for chronic pain management. The platform uses machine learning to identify patients at risk of opioid misuse and recommends personalized care plans.

Community Outreach

The company sponsors the Pain Awareness Campaign, a national initiative that provides educational materials to schools, workplaces, and community centers. The campaign includes workshops, webinars, and a public service announcement series on the risks of unmanaged pain.

Research Funding

411pain allocates 2 percent of its annual revenue to research grants focused on pain mechanisms and treatment modalities. Grants are awarded through a peer‑review process overseen by an independent advisory board.

Environmental Sustainability

In alignment with corporate sustainability goals, 411pain has implemented a recycling program for its packaging materials and reduced carbon emissions by 15 percent through logistics optimization. The company also participates in the Green Healthcare Initiative to promote eco‑friendly practices in clinical settings.

Corporate Governance

Board of Directors

The board comprises ten members with expertise in medicine, finance, technology, and regulatory affairs. The board meets quarterly and oversees executive performance, risk management, and strategic planning.

Executive Compensation

Executive compensation at 411pain is structured to align with long‑term shareholder value. The compensation package includes base salary, annual performance bonuses, and equity awards tied to market‑cap thresholds.

Risk Management

411pain maintains a risk management committee that monitors operational, financial, and compliance risks. The committee issues annual risk reports that are filed with the Securities and Exchange Commission.

Financial Performance

Revenue Trends

Over the past decade, 411pain has shown consistent revenue growth. Key milestones include:

2015: $25 million in total revenue.
2018: $65 million following the IPO.
2020: $120 million amid the COVID‑19 pandemic.
2023: $250 million, reflecting the expansion of digital services.

Profitability

The company achieved operating profitability in 2016, with a gross margin of 48 percent. Net income margin improved from 4 percent in 2016 to 12 percent in 2023, largely due to the scale of the telehealth platform and economies of scale in manufacturing.

Capital Structure

As of 2024, 411pain’s capital structure includes $300 million in equity, $150 million in long‑term debt, and $50 million in preferred stock. The company maintains a debt‑to‑equity ratio below 0.5, indicating a conservative leverage profile.

Future Outlook

Product Pipeline

411pain is actively developing a next‑generation transdermal patch that incorporates micro‑encapsulation technology to provide sustained release of analgesics over 72 hours. The product is expected to enter phase‑III clinical trials in 2025.

Geographic Expansion

Plans include entry into the European Union market, targeting Germany, France, and Spain. The company also seeks to increase market penetration in Canada through direct‑to‑consumer digital services.

Digital Innovation

Upcoming initiatives focus on integrating artificial intelligence into clinical decision support tools and expanding the company’s data analytics offerings to third‑party payers.

References

1. Johnson, M. “Digital Transformation in Pain Management.” Journal of Health Informatics, 2019.

2. Smith, L. “Opioid Stewardship: Balancing Efficacy and Safety.” Pain Medicine Review, 2020.

3. Federal Drug Administration. “Regulatory Guidelines for Over‑the‑Counter Pain Products.” 2021.

4. National Institutes of Health. “Grant Records for Pain Research, 2022.”

5. United States Securities and Exchange Commission. “Annual Report 2023.”

6. HealthData Inc. “Partnership Agreement with 411pain.” 2021.

7. Green Healthcare Initiative. “Sustainability Report 2023.”

External Links

411pain’s official corporate website, regulatory filings, and patient resources are maintained for reference and public accessibility.

Search

Table of Contents